2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades
If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a ...
Eli Lilly to end 2024 among best in Big Pharma; Novo among worst
Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...
health.wusf.usf.edu13h
FDA declares the shortage of obesity drug Zepbound has ended. The results are complicated
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
FDA Zepbound shortage ends, impacts patients, compounding pharmacies
During FDA-declared shortages, pharmacists can legally make compounded versions of brand-name medications. But drugmakers and ...
israelnewsonline13h
Eli Lilly's Obesity Drug Beats Rivals Head-to-Head – Cramer Expects Shares to Rise Next
A sign with the company logo stands in front of the Eli Lilly and Company headquarters campus in Indianapolis, Indiana, on March 17, 2024. New study data has solidified the club's position Eli Lillyis ...
MedPage Today on MSN13hOpinion
CMS Moved to Expand Obesity Drug Coverage. Private Insurers Need to Step Up.
This proposed rule signals an important shift in the federal approach to obesity management, aligning with the medical ...